ATE230759T1 - Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2 - Google Patents

Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2

Info

Publication number
ATE230759T1
ATE230759T1 AT96309211T AT96309211T ATE230759T1 AT E230759 T1 ATE230759 T1 AT E230759T1 AT 96309211 T AT96309211 T AT 96309211T AT 96309211 T AT96309211 T AT 96309211T AT E230759 T1 ATE230759 T1 AT E230759T1
Authority
AT
Austria
Prior art keywords
breast cancer
relates
brca2
human
gene
Prior art date
Application number
AT96309211T
Other languages
English (en)
Inventor
Sean V Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M Rommens
Barbara L Weber
Original Assignee
Myriad Genetics Inc
Endorecherche Inc
Univ Pennsylvania
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE230759(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Myriad Genetics Inc, Endorecherche Inc, Univ Pennsylvania, Hsc Res Dev Lp filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of ATE230759T1 publication Critical patent/ATE230759T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96309211T 1995-12-18 1996-12-17 Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2 ATE230759T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57377995A 1995-12-18 1995-12-18
US57535995A 1995-12-20 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene

Publications (1)

Publication Number Publication Date
ATE230759T1 true ATE230759T1 (de) 2003-01-15

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96309211T ATE230759T1 (de) 1995-12-18 1996-12-17 Chromosom 13 verbundene brustkrebsempfindlichkeitsgen brca2

Country Status (11)

Country Link
US (2) US6124104A (de)
EP (1) EP0785216B2 (de)
JP (1) JP3455228B2 (de)
AT (1) ATE230759T1 (de)
AU (1) AU1461597A (de)
CA (1) CA2239733C (de)
DE (1) DE69625678T3 (de)
IL (1) IL124620A0 (de)
NO (1) NO982785L (de)
NZ (1) NZ326525A (de)
WO (1) WO1997022689A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
WO1998025125A2 (en) * 1996-12-03 1998-06-11 Swift Michael R Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
EP2275574B1 (de) * 1997-08-15 2015-06-03 Gene Logic Inc. Menschliche BRCA2-Gen-kodierende Sequenzhaplotypen
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
EP2298878A3 (de) 2000-11-03 2011-11-16 Dana Farber Cancer Institute Zusammensetzungen und verfahren zur krebsdiagnose
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
CA2449647A1 (en) * 2001-06-05 2002-12-12 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
WO2003044212A2 (en) * 2001-11-16 2003-05-30 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate brca2 and methods of use
CN1310652C (zh) * 2001-11-29 2007-04-18 特拉科斯有限公司 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
EP1896607A4 (de) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
EP1888776A4 (de) * 2005-05-19 2009-07-29 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
MX2007014220A (es) * 2005-05-19 2009-02-16 Synergenz Bioscience Ltd Metodos para la valoracion del riesgo de desarrollar cancer de pulmon usando un analisis de polimorfismos geneticos.
EP1888779A4 (de) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Verfahren zur analyse von polymorphismen sowie verwendungen davon
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2470998C2 (ru) * 2006-06-22 2012-12-27 Ян Любински Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US7993835B1 (en) * 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
EP2324127B1 (de) 2008-08-10 2015-01-21 Kuakini Medical Center Verfahren zur verwendung von foxo3a-polymorphismen und haplotypen zur prognose und förderung von gesundem altern und langlebigkeit
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
CN109979526B (zh) * 2014-03-25 2023-11-24 凡弗3基因组有限公司 用于功能证实癌症突变的rna分析的系统和方法
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US6045997A (en) † 1995-11-23 2000-04-04 Duke University Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
CA2289109A1 (en) † 1997-04-30 1998-11-05 Genzyme Limited Carbohydrate-deficient glycoprotein syndrome type i
WO1998055650A1 (en) † 1997-06-04 1998-12-10 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
HUP0300391A3 (en) † 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma
EP1280814A4 (de) † 2000-04-13 2003-05-14 Genaissance Pharmaceuticals Assoziation der haplotypen des beta2 adrenergenen rezeptors mit der medikamentenwirksamkeit
EP1430081A2 (de) † 2001-06-13 2004-06-23 Centre National De La Recherche Scientifique (Cnrs) Molekuläre komplexe brca1/acc alpha, diagnostische und therapeutische verwendungen

Also Published As

Publication number Publication date
EP0785216B2 (de) 2006-06-07
WO1997022689A1 (en) 1997-06-26
JP3455228B2 (ja) 2003-10-14
DE69625678T2 (de) 2003-11-06
DE69625678D1 (de) 2003-02-13
NZ326525A (en) 1999-11-29
NO982785D0 (no) 1998-06-17
US6124104A (en) 2000-09-26
CA2239733A1 (en) 1997-06-26
DE69625678T3 (de) 2006-11-09
IL124620A0 (en) 1998-12-06
EP0785216B1 (de) 2003-01-08
NO982785L (no) 1998-08-17
EP0785216A1 (de) 1997-07-23
AU1461597A (en) 1997-07-14
US6033857A (en) 2000-03-07
CA2239733C (en) 2001-04-03

Similar Documents

Publication Publication Date Title
DE69625678D1 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
EP1260520A3 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
WO1996005307A3 (en) 17q-linked breast and ovarian cancer susceptibility gene
WO1996005306A3 (en) In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
Karim et al. Apparent genotype–phenotype correlation in childhood, adolescent, and adult Chediak‐Higashi syndrome
ATE181559T1 (de) Proteinkinase
Al-Khersan et al. A novel MERTK mutation causing retinitis pigmentosa
Lin et al. A novel pathogenic HSPG2 mutation in Schwartz–Jampel syndrome
Adams et al. Role of genetic factors in drug-related autoimmunity
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
Al‐Muhaizea et al. Genetics of ataxia telangiectasia in a highly consanguineous population
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
Skrzypczak et al. MYH gene status in polish FAP patients without APC gene mutations
ATE346150T1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0785216

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0785216

Country of ref document: EP